Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection
Hypertension, Hypertrophy
About this trial
This is an interventional other trial for Hypertension
Eligibility Criteria
Inclusion Criteria
- Written consent
- Age: 19 to 50 in Arm 1, 30 to 75 in Arm 2
- Group 2A and 2E participants have left-ventricular hypertrophy
- Group 2B and 2F participants have diagnosed hypertrophic cardiomyopathy
- Group 2C and 2G participants are stable outpatients with NYHA class 1-3 heart failure with evidence of elevated LV mass (LVH), irrespective of LVEF.
- Group 2D and 2H participants are stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents
Exclusion Criteria
- Contraindications to MRI or MRI contrast agents
- Hemoglobin ≤ 9.0 gm/dL (only Group 2 participants)
- Glomerular filtration rate (based on MDRD Equation) < 30 ml/min/1.73m2 (only Group 2 participants)
- Any condition leading to a life expectancy <1 year
- Medically diagnosed claustrophobia
- Have received, or are scheduled to receive, another investigational medicinal product from 1 month prior to 1 month after inclusion in this study
- BMI of less than 18.5 or greater than 32
- Group 1: medically diagnosed heart disease
Sites / Locations
- Sunnybrook Health Sciences CentreRecruiting
- St. Michael's Hospital
Arms of the Study
Arm 1
Arm 2
Other
Other
Healthy Volunteers
Hypertension Hypertrophy Volunteers
Arm 1 Group 1A: control male volunteers between 19 and 50 years of age. Group 1B: control female volunteers between 19 and 50 years of age. Group 1C: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice Group 1D: control male volunteers between 19 and 50 years of age. Group 1E: control female volunteers between 19 and 50 years of age. Group 1F: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice
Arm 2 Group 2A: patients aged 30 to 75 with hypertension and hypertrophy Group 2B: patients aged 30 to 75 with non-obstructive hypertrophic cardiomyopathy (HCM). Group 2C: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF. Group 2D: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents. Group 2E: patients aged 30 to 75 with hypertrophy Group 2F: patients aged 30 to 75 with hypertrophic cardiomyopathy (HCM). Group 2G: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF. Group 2H: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents.